Healius share price on watch after trading update

The Healius Ltd (ASX: HLS) share price is on watch as the Aussie healthcare company provided a trading update at its AGM today.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Healius Ltd (ASX: HLS) share price is on watch this morning after a trading update provided at the company's annual general meeting (AGM).

What could move the Healius share price?

While shareholders are waiting to hear from management at the AGM, all eyes will be on the company's trading and management update released this morning.

Healius announced underlying net profit after tax (NPAT) for FY20 is expected to be between $94 million and $102 million, which could see the Healius share price move today.

At the top end of that range, this would represent a 9.4% increase on the prior corresponding period (pcp) as anticipated in the company's 16 August update. Healius would then have delivered in line with the seasonally adjusted run rate from 2H 2019.

The Aussie healthcare company also confirmed a raft of management changes in today's announcement. Scott Beattie will be taking over as CEO of the group's Medical Centres business. These changes all form part of Healius' organisational re-design, which was announced earlier this year.

What else did Healius announce?

Chairman Rob Hubbard noted FY19 was a big year for the Aussie healthcare group. The company rebranded as Healius during the year and rejected a takeover bid from its major shareholder, Jangho, due to share price and conditionality.

In terms of financials, Healius delivered revenue up 6% on pcp to $1.8 billion with underlying NPAT up 6.5% to $93 million as the Healius share price climbed higher in 2019.

Pathology was the company's largest division, with about 60% of the group's profit on the back of a 2H 2019 turnaround. Healius' Medical Centres division grew revenue and EBIT by 13% and 19%, respectively, and the Imaging division delivered a third successive year of double-digit growth.

Mr. Hubbard said FY20 will be the peak year of adjustments to the company's reported earnings. 

Capital expenditure remained higher in FY19, mostly due to strategic investments such as its Montserrat Day Hospitals acquisition.

The Healius share price is up 27.87% to $3.12 per share, prior to this morning's open.

Motley Fool contributor Kenneth Hall has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

Could CSL shares outperform the ASX 200 in 2026?

After shocking investors in 2025, CSL shares may be setting up for a comeback. Here’s why 2026 could look better.

Read more »

A man holds his head in his hands after seeing bad news on his laptop screen.
Healthcare Shares

Why did CSL shares crash 39% in 2025?

Should you be buying the dip? Let's find out.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Why 4DMedical shares are jumping 14% today

4DMedical shares climb on a new CFO appointment as investors focus on US expansion and rising use of its lung…

Read more »

A business woman flexes her muscles overlooking a city scape below.
Healthcare Shares

Why I plan to buy this incredible ASX 200 stock in 2026

A 33% pullback has put Pro Medicus back in focus. Here’s why I’m preparing to buy its shares in 2026.

Read more »

research with microscope
Healthcare Shares

This ASX healthcare stock just changed its debt. Here's why it matters

Shares in Mesoblast edge higher after the company announces a major change to its debt and funding structure.

Read more »

stock growth chart
Healthcare Shares

Will CSL shares crash again in 2026?

CSL shares have fallen almost 40% in 2025. Investors are now asking if the worst is already behind the stock.

Read more »

Stethoscope with a piggy bank and hundred dollar notes.
Healthcare Shares

Here's the dividend forecast out to 2030 for Sigma shares

This business could pay healthy dividends in the coming years…

Read more »

A medical researcher rests his forehead on his fist with a dejected look on his face while sitting behind a scientific microscope with another researcher's hand on his shoulder as if giving comfort.
Healthcare Shares

Mayne Pharma signals short-term pain as it resets for growth

It has been a turbulent year for Mayne Pharma after the terminated takeover bid by US company Cosette Pharmaceuticals.

Read more »